Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2023 08:30 ET | Source: Cellectar Biosciences

Cellectar Provides a Research and Development Program Summary

Waldenstrom’s macroglobulinemia pivotal trial top-line data now expected second half of 2023; pediatric high-grade glioma trial to initiate in Q3 Phospholipid drug conjugate platform validation with...
May 04, 2023 09:22 ET | Source: Cellectar Biosciences

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
May 04, 2023 08:40 ET | Source: Cellectar Biosciences

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
March 09, 2023 08:40 ET | Source: Cellectar Biosciences

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...
March 08, 2023 16:05 ET | Source: Cellectar Biosciences

Cellectar to Participate at Upcoming Banking Conferences

FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
February 28, 2023 08:30 ET | Source: Cellectar Biosciences

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
February 15, 2023 08:30 ET | Source: Cellectar Biosciences

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
November 30, 2022 08:30 ET | Source: Cellectar Biosciences

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
November 21, 2022 08:30 ET | Source: Cellectar Biosciences

Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

FLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
November 16, 2022 08:30 ET | Source: Cellectar Biosciences

Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

FLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...